Table 1

Effects of signal pathway probe inhibitors on agonist-induced contractions

Compound (μM)	Signal Path Target	Effects^1-a on Contractions by
Compound (μM)	Signal Path Target	TFLLR-NH₂	EGF	AA
CP118,556/PP1 (1)	src-kinase	I	I	^1-b
Tyrphostin-47/AG213 (20)	tyrosine kinase	I	I	^1-b
Genistein (8)	tyrosine kinase	I	I	N.D.
Indomethacin (3)	cyclooxygenase	I	I	I
U57, 908 (20)	diacylglycerol lipase	I	I	N.D.
GF109203X (1)	kinase C	^1-cI (50%)	I	^1-b
PD98059 (2)	MAP-kinase-kinase	I	I	^1-b
Wortmannin (0.1)	PI3-kinase	^1-cI (58%)	I	^1-b
Wortmannin (0.1) plus GF109203x (1)	PI3-kinase plus kinase C	I	N.D.	N.D.
LY294002 (2.5)	PI3-kinase	^1-cI (58%)	I	^1-b
PD153035 (1)	EGF-receptor kinase	^1-b	I	N.D.
Nifedipine	Ca²⁺channel	I	I	I

The concentration of agonists were TFLLR-NH₂, 1 μM; EGF 17 nM and AA, 10 μM.
↵1-a I, Inhibition.
↵1-b O, No effect.
↵1-c I, Partial inhibition (%).